Keywords: amylin, ac2993, meets, endpoints, ph, ii, trial

Amylin's AC2993 meets endpoints in Ph II trial

Article | 29 June 2001

Amylin Pharmaceuticals presented positive results from a Phase II studyof its diabetes drug candidate, AC2993 (synthetic exendin-4) at the recent ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Amylin

Go to company listing